The last few months have been very eventful for LIDDS; the last patient has been enrolled in their localized treatment of prostate cancer study and they are evaluating a possible listing on Nasdaq Stockholm’s Main Market. The CEO of LIDDS, Monica Wallter, gives us an update.
What’s next for LIDDS and what results can we expect during 2019?
“LIDDS will report the Phase IIb study after the summer. Also, the Phase I study where solid tumors are injected with NanoZolid combined with docetaxel is ongoing and the first patient is treated. We have a preclinical program ongoing with STING agonists and additionally, very interesting, other immune-oncology projects are in feasibility stage. Other highlights this year include the hiring of Charlotta Gauffin as Head of Clinical Development, and Markus Thor as Head of Business Development. We have been invited to present the possibilities with the NanoZolid technology at the following conferences: Associate Professor Niklas Axén, Inventor and Head of Technology and Patents, attended the Pharma R&D Conference in Paris in March, and Stefan Grudén, Director of Pharmaceutical R&D, will present at the Formulation & Drug Delivery Congress in London in April.”
What are your hopes and expectations for the future?
“That LIDDS will be able to outlicense the clinical projects in prostate cancer and local cytostatic treatment of solid tumors after results are available. Additionally, that new projects will enter into clinical stage the coming years.”
You are evaluating a possible listing, what are the advantages?
“A listing on Nasdaq Stockholm’s Main Market is a natural next step in the company’s development. Hopefully it contributes to increased interest from a broader investor base as well as increased visibility, both in Sweden and globally.”
LIDDS AB develops injectable drugs for cancer and other diseases based on a NanoZolid technology. NanoZolid helps solve some of the main problems with the way drugs work in the body and which affect patient quality of life. NanoZolid enables the controlled, long-term and personalized release of drugs for up to six months. NanoZolid can be combined with traditional small molecules as well as with larger molecules.
Photo of Monica Wallter: LIDDS